3.04

4.90% 0.18

Aadi Bioscience Inc (AADI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AADI Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.86

Aprire:

$2.8

Volume 24 ore:

247.87K

Relative Volume:

0.95

Capitalizzazione di mercato:

$71.23M

Reddito:

$23.26M

Utile/perdita netta:

$-63.41M

Rapporto P/E:

-1.2459

EPS:

-2.44

Flusso di cassa netto:

$-64.56M

1 W Prestazione:

+25.53%

1M Prestazione:

+30.44%

6M Prestazione:

+71.43%

1 anno Prestazione:

+52.29%

Intervallo 1D:

$2.7519

$3.04

Intervallo di 1 settimana:

$2.07

$3.60

Portata 52W:

$1.21

$3.60

Aadi Bioscience Inc Stock (AADI) Company Profile

Nome

Aadi Bioscience Inc

Settore

Healthcare (1177)

Industria

Biotechnology (680)

Telefono

424-473-8055

Indirizzo

17383 SUNSET AVENUE, PACIFIC PALISADES

Dipendente

Cinguettio

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

AADI's Discussions on Twitter

Confronta AADI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AADI Aadi Bioscience Inc	3.00	71.23M	23.26M	-63.41M	-64.56M	-2.36
VRTX Vertex Pharmaceuticals Inc	407.57	105.01B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	714.47	78.17B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	629.39	37.48B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	243.25	30.94B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.13	27.15B	3.30B	-501.07M	1.03B	-2.1146

Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-27	Downgrade	Piper Sandler	Overweight → Neutral
2024-08-21	Downgrade	Jefferies	Buy → Hold
2024-08-21	Downgrade	TD Cowen	Buy → Hold
2023-12-15	Downgrade	H.C. Wainwright	Buy → Neutral
2022-01-11	Iniziato	Jefferies	Buy
2021-10-01	Iniziato	Cowen	Outperform
2021-09-14	Iniziato	Ladenburg Thalmann	Buy
2021-09-08	Iniziato	Piper Sandler	Overweight

Mostra tutto

Aadi Bioscience Inc Borsa (AADI) Ultime notizie

Dec 23, 2024

Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World

Dec 23, 2024

Dec 22, 2024

Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini

Dec 20, 2024

Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Scrip

Dec 20, 2024

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga

Dec 20, 2024

Aadi Bioscience stock soars on licensing and sale deals - Investing.com India

Dec 20, 2024

Dec 19, 2024

Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com

Dec 19, 2024

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance

Dec 19, 2024

Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com

Dec 19, 2024

Clinical Trials News Live Feed - StockTitan

Dec 19, 2024

Dec 15, 2024

Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat

Dec 15, 2024

Dec 11, 2024

AADI Enlists NY Court To Enforce Cancer Drug Award - Law360

Dec 11, 2024

Dec 03, 2024

Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 03, 2024

Dec 02, 2024

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 8.8% - MarketBeat

Dec 02, 2024

Nov 26, 2024

GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World

Nov 26, 2024

Nov 19, 2024